Free Trial
→ Elon pays this company. Every time. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$0.96
-4.0%		$1.08
$0.74
▼
$1.74
$30.18M0.26145,217 shs75,262 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.70
-0.2%		$3.79
$2.60
▼
$14.68
$32.20M1.21316,116 shs47,518 shs
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$0.84
-3.7%		$0.89
$0.68
▼
$3.68
$9.91M0.06215,438 shs6,478 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$0.87
-5.7%		$1.15
$0.86
▼
$3.95
$32.68M0.69196,407 shs273,216 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-5.71%-9.95%-28.61%+8.65%-37.92%
Briacell Therap stock logo
BCTX
Briacell Therap
-4.13%-7.71%+2.20%-5.84%-67.11%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
+7.22%-6.43%+11.28%-11.68%-54.92%
Metagenomi, Inc. stock logo
MGX
Metagenomi
-10.07%-10.94%-20.92%-28.89%-67.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$0.96
-4.0%		$1.08
$0.74
▼
$1.74
$30.18M0.26145,217 shs75,262 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.70
-0.2%		$3.79
$2.60
▼
$14.68
$32.20M1.21316,116 shs47,518 shs
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$0.84
-3.7%		$0.89
$0.68
▼
$3.68
$9.91M0.06215,438 shs6,478 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$0.87
-5.7%		$1.15
$0.86
▼
$3.95
$32.68M0.69196,407 shs273,216 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-5.71%-9.95%-28.61%+8.65%-37.92%
Briacell Therap stock logo
BCTX
Briacell Therap
-4.13%-7.71%+2.20%-5.84%-67.11%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
+7.22%-6.43%+11.28%-11.68%-54.92%
Metagenomi, Inc. stock logo
MGX
Metagenomi
-10.07%-10.94%-20.92%-28.89%-67.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00405.05% Upside
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
2.00
Hold$4.16388.84% Upside
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.75
Moderate Buy$6.00560.79% Upside

Current Analyst Ratings Breakdown

Latest GDTC, MGX, ATNM, and BCTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/22/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/15/2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
Fundamental Research logo
Fundamental Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price TargetBuy$4.16
9/9/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/12/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$7.00
7/23/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M0.89N/AN/A$1.31 per share0.76
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$250K40.27N/AN/A$0.45 per share1.89
Metagenomi, Inc. stock logo
MGX
Metagenomi
$25.21M1.36N/AN/A$4.22 per share0.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
-$3.10MN/AN/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.49N/AN/AN/A-384.61%-63.65%-44.52%11/10/2026 (Estimated)

Latest GDTC, MGX, ATNM, and BCTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.6395N/AN/AN/A$2.58 millionN/A
9/30/2026H1 2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A-$0.06N/A-$0.06N/A$0.06 million
8/10/2026Q2 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.5531-$0.73-$0.1769-$0.73$3.01 million($0.26) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.07
2.64
N/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
4.50
4.50

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.04%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
48.70 million8.64 millionNo Data
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
4211.83 millionN/ANot Optionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
11337.78 million33.06 millionN/A

Recent News About These Companies

Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
October 13 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379598/0/en/metagenomi-therapeutics-inc-to-participate-in-the-chardan-10th-annual-healthcare-conference.html
Metagenomi (NASDAQ:MGX) Stock Price Down 7.7% - What's Next?
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081488
Metagenomi updates hemophilia A gene editing program
September 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/metagenomi-updates-hemophilia-a-gene-editing-program?utm_source=marketbeat.com&utm_medium=referral
Metagenomi (NASDAQ:MGX) Director Laurence Reid Purchases 20,000 Shares of Stock
September 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mgx-insider-buying-and-selling-2026-09-12/
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354046/0/en/metagenomi-therapeutics-inc-to-present-at-the-wells-fargo-21st-annual-healthcare-conference.html
Metagenomi Therapeutics Inc MGX
August 25, 2026  |  morningstar.comM
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
August 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-metagenomi-therapeutics-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302859292.html
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938987-mgx-resources-limited-mtgry-q4-2026-earnings-call-prepared-remarks-transcript
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)
August 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3794251/analysts-top-healthcare-picks-metagenomi-inc-mgx-kymera-therapeutics-kymr/
Metagenomi Therapeutics: Q2 Earnings Snapshot
August 10, 2026  |  chron.comhttps://www.chron.com/business/article/metagenomi-therapeutics-q2-earnings-snapshot-22382477.php
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/metagenomi-therapeutics-reports-business-updates-and-second-quarter-2026-financial-results-1036437877
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972338/metagenomi-therapeutics-mgx-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2972338
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
July 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923569-mgx-resources-limited-mtgry-q4-2026-earnings-call-transcript
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327674/30541/en/prolynx-names-simon-harnest-as-chief-financial-officer-and-amer-mirza-phd-as-chief-scientific-officer-as-it-advances-multi-program-obesity-and-metabolic-disease-portfolio.html
Metagenomi Announces Board Changes and Shareholder Meeting Results
June 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/metagenomi-announces-board-changes-and-shareholder-meeting-results?utm_source=marketbeat.com&utm_medium=referral
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
June 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-metagenomi-therapeutics-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302792930.html
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302769/0/en/metagenomi-therapeutics-inc-to-present-at-the-jefferies-global-healthcare-conference.html
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/metagenomi-therapeutics-mgx-price-target-decreased-by-1071-to-850/ar-AA23aNXU
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/metagenomi-therapeutics-inc-nasdaq-mgx-134209184.html
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/metagenomi-therapeutics-reports-business-updates-and-first-quarter-2026-financial-results-1036139191

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$0.97 -0.03 (-3.25%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$3.70 -0.01 (-0.24%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

CytoMed Therapeutics stock logo

CytoMed Therapeutics NASDAQ:GDTC

$0.84 -0.03 (-3.68%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$0.86 -0.05 (-5.70%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas